Rutgers New Jersey Medical School will be a clinical test site for a study assessing the long term risk of chronic kidney disease in patients who recover from COVID-19. The Multi-Center Assessment of Survivors for Kidney Disease after COVID-19 (MASKeD-COVID) study – conducted by the Division of Nephrology at Mount Sinai – will assess risk in up to 4,000 patients who have recovered from COVID-19 using the artificial-intelligence diagnostic system KidneyIntelX that can incorporate novel protein biomarkers and provide insight into the disease. Researchers will also study patients’ COVID-19 antibody levels over time, which will provide insights into the interaction between immune response and kidney-related complications. Initial research findings are expected to be reported in early 2021. To read the full story.
Recent Posts
- Estrogen Patch Shortages Are Ongoing—Here’s Where to Find Them and What to Ask Your Doctor.
- Toddlers are getting their hands on e-cigarettes and inhaling at an alarming rate, new Rutgers study shows.
- Rutgers deans: We train advanced practice nurses for N.J. Our laws send them elsewhere.
- Push for raw milk intensifies across the US, despite illness outbreaks and scientists’ warnings.
- Princeton undergraduates build real-world skills through community health micro-internships.
Categories
- Community (2,494)
- Covid (1,001)
- CTO Events (6)
- News (3,166)
- Pilots (21)